title: Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial.
authors.forename: Rodney P E
authors.initials: RP
authors.lastname: Pollard
authors.forename: Wayel H
authors.initials: WH
authors.lastname: Abdulahad
authors.forename: Arjan
authors.initials: A
authors.lastname: Vissink
authors.forename: Nishath
authors.initials: N
authors.lastname: Hamza
authors.forename: Johannes G M
authors.initials: JG
authors.lastname: Burgerhof
authors.forename: Jiska M
authors.initials: JM
authors.lastname: Meijer
authors.forename: Annie
authors.initials: A
authors.lastname: Visser
authors.forename: Minke G
authors.initials: MG
authors.lastname: Huitema
authors.forename: Fred K L
authors.initials: FK
authors.lastname: Spijkervet
authors.forename: Cees G M
authors.initials: CG
authors.lastname: Kallenberg
authors.forename: Hendrika
authors.initials: H
authors.lastname: Bootsma
authors.forename: Frans G M
authors.initials: FG
authors.lastname: Kroese
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D053264:B-Cell Activating Factor / Q000097:blood*; D004311:Double-Blind Method; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D000069283:Rituximab; D012859:Sjogren's Syndrome / Q000097:blood* / Q000188:drug therapy*; D053300:Tumor Necrosis Factor Ligand Superfamily Member 13 / Q000097:blood*
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D053264:B-Cell Activating Factor; C505719:TNFSF13B protein, human; D053300:Tumor Necrosis Factor Ligand Superfamily Member 13; D000069283:Rituximab